Mohamed Galal EL-Shahat Mohamed EL-Melegy

@alexu.edu.eg

Department of Pharmaceutics - Faculty of Pharmacy
Alexandria University

Mohamed Galal EL-Shahat Mohamed EL-Melegy


                  Download Compact PDF  
https://researchid.co/mohamed.elmelegy
Mohamed G.El-Melegy is currently working as an assistant lecturer at the Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University. Mohamed does advanced research in the nanotechnology of drug delivery systems, Phytopharmaceuticals, synthetic drugs, cancer, and gene therapies. The Master's degree thesis entitled "Improvement of Permeability of Some Selected Drugs through the Formulation of Lipid Nanosystems"

EDUCATION

- 2017: B.Sc. of Pharmaceutical Sciences, with a general grade of "Top 1% with Distinction Honors" (A+), Faculty of Pharmacy, Alexandria University, Egypt.
- 2021: M.Sc. in Pharmaceutical Sciences, Faculty of Pharmacy, Alexandria University, Egypt. Thesis entitled: "Improvement of Permeability of Some Selected Drugs through the Formulation of Lipid Nanosystems".

RESEARCH INTERESTS

Pharmaceutical Nanotechnology
Drug Delivery Systems
Lipid / Polymeric Nanoparticles
Phytopharmaceuticals
Cancer and Gene Therapies
RNAs Therapeutics
Microfluidic-based Nanocarriers
Smart Targeted Nanomedicine
2

Scopus Publications

29

Scholar Citations

2

Scholar h-index

1

Scholar i10-index

Scopus Publications

  • Stable self-assembled oral metformin-bridged nanocochleates against hepatocellular carcinoma
    Mohamed G. El-Melegy, Amal H. El-Kamel, Radwa A. Mehanna, Ahmed Gaballah, Hoda M. Eltaher
    Drug Delivery and Translational Research, 2025
    Despite its established anti-diabetic activity, Metformin hydrochloride (MET) has been repurposed for the management of hepatocellular carcinoma (HCC). Owing to MET high aqueous solubility and poor oral permeability, a novel nanoplatform is sought to overcome the current challenges of traditional formulations. In this study, we developed MET-bridged nanocochleates (MET-CO) using a direct bridging method followed by optimization and assessment using various in-vitro and in-vivo pharmacokinetic methods. The optimized nanocochleates MET-CODCP 19, containing dicetyl phosphate (DCP), displayed uniform snail-shaped nano-rolls measuring 136.41 ± 2.11 nm with a PDI of 0.241 ± 0.005 and a highly negative ζ-potential of -61.93 ± 2.57 mV. With an impressive MET encochleation efficiency (> 75%), MET-CODCP 19 exhibited a controlled biphasic release profile, with minimal initial burst followed by prolonged release for 24 h. Importantly, they showed significant MET permeation in both in-vitro Caco-2 and ex-vivo intestinal models compared to non-DCP containing formula or MET solution. The in-vivo oral bioavailability study demonstrated pronounced improvements in the pharmacokinetic parameters with a 5.5 relative bioavailability compared to MET solution. Notably, a significant reduction in IC50 values in HepG2 cells after 24 h of treatment was observed. Furthermore, the optimized formulation showed a significant downregulation of anti-apoptotic and cancer stemness genes, with 12- and 2-fold lower expression compared to MET solution. These promising results highlight the efficacy of the novel MET-bridged nanocochleates as a stable nanoplatform for enhancing the oral bioavailability of MET and boosting its anticancer potential against HCC. Graphical Abstract
  • Enhanced oral permeability of Trans-Resveratrol using nanocochleates for boosting anticancer efficacy; in-vitro and ex-vivo appraisal
    Mohamed G. El-Melegy, Hoda M. Eltaher, Ahmed Gaballah, Amal H. El-Kamel
    European Journal of Pharmaceutics and Biopharmaceutics, 2021

RECENT SCHOLAR PUBLICATIONS

  • Stable self-assembled oral metformin-bridged nanocochleates against hepatocellular carcinoma
    MG El-Melegy, AH El-Kamel, RA Mehanna, A Gaballah, HM Eltaher
    Drug Delivery and Translational Research 15 (6), 2064-2086 , 2025
    2025
    Citations: 5
  • Enhanced oral permeability of Trans-Resveratrol using nanocochleates for boosting anticancer efficacy; in-vitro and ex-vivo appraisal
    MG El-Melegy, HM Eltaher, A Gaballah, AH El-Kamel
    European Journal of Pharmaceutics and Biopharmaceutics 168, 166-183 , 2021
    2021
    Citations: 24

MOST CITED SCHOLAR PUBLICATIONS

  • Enhanced oral permeability of Trans-Resveratrol using nanocochleates for boosting anticancer efficacy; in-vitro and ex-vivo appraisal
    MG El-Melegy, HM Eltaher, A Gaballah, AH El-Kamel
    European Journal of Pharmaceutics and Biopharmaceutics 168, 166-183 , 2021
    2021
    Citations: 24
  • Stable self-assembled oral metformin-bridged nanocochleates against hepatocellular carcinoma
    MG El-Melegy, AH El-Kamel, RA Mehanna, A Gaballah, HM Eltaher
    Drug Delivery and Translational Research 15 (6), 2064-2086 , 2025
    2025
    Citations: 5

Publications

Enhanced oral permeability of Trans-Resveratrol using nanocochleates for boosting anticancer efficacy; in-vitro and ex-vivo appraisal
MG El-Melegy, HM Eltaher, A Gaballah, AH El-Kamel
European Journal of Pharmaceutics and Biopharmaceutics 168, 166-183 2021